Quick Answer
Silexion Therapeutics Corp reported Cash and Equivalents of $5.99 million for fiscal year 2025.
Silexion Therapeutics Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.99M | +404.7% |
| 2024 | $1.19M | -74.2% |
| 2023 | $4.59M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.24M | +368.5% | +166.7% |
| June 30, 2025 | $3.47M | +104.2% | -43.7% |
| March 31, 2025 | $6.15M | — | +418.3% |
| December 31, 2024 | $1.19M | -74.2% | -39.8% |
| September 30, 2024 | $1.97M | — | +16.3% |
| June 30, 2024 | $1.70M | -73.7% | -63.1% |
| December 31, 2023 | $4.59M | — | -28.7% |
| June 30, 2023 | $6.44M | — | — |
- Silexion Therapeutics Corp showed an increase of +404.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Silexion Therapeutics Corp’s cash and equivalents has grown by 30.4% (from $4.59 million to $5.99 million).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: